Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Seyed Alavian; Behzad Hajarizadeh; Bashir Hajibeigi; Taher Doroudi; Amir Hamadanizadeh; Koroush Abar

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Author(s):

Seyed Moayed Alavian^1,*,

Behzad Hajarizadeh²,

Bashir Hajibeigi²,

Taher Doroudi²,

Amir Kambiz Hamadanizadeh²,

Koroush Abar²

1Baqiyatallah University of Medical Sciences, Tehran Hepatitis Center, Study Group of Interferonin Iran, [email protected], Tehran, IR.Iran

2Baqiyatallah University of Medical Sciences, Tehran Hepatitis center, Tehran, IR.Iran

Hepatitis Monthly:Vol. 4, issue 7; 53-58

Published online:Sep 30, 2004

Article type:Research Article

How to Cite:Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:

Abstract

Background and Aims: Pegylation of Interferon (IFN) prolongs the medication half-life, which has resulted in introducing Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C. This clinical trial was conducted to assess the efficacy and safety of Peg-INF in combination with ribavirin in a number of Iranian patients with chronic hepatitis C or cirrhosis.

Methods: Fifty two patients with HCV RNA in serum, persistently elevated aminotransferase levels, and chronic hepatitis (n=45) or cirrhosis (n=7) on liver biopsy were enrolled to this study. The patients received PEG-IFN (40 kD) 180 micg per week plus ribavirin 10-15 mg/kg per day. Treatment lasted 48 weeks and was followed by a 24-week follow up period to assess sustained virologic response (SVR). The patients consisted of 46 males and 6 females with a mean age of 38.5 ± 10.9 years.

Results: In an intention-to-treat analysis HCV RNA was undetectable in 43 patients (83.7%) at week 48 and SVR was achieved in 28 patients (53.8%). SVR was achieved in 62.9% of naive patients, 35.3% of the patients who had a past failed treatment with IFN-based therapy, 60.0% of patients with chronic hepatitis and 14.3% of cirrhotic patients. In two patients (3.8%) adverse event led to treatment discontinuation and in eight patients (15.3%) dose modification of medication was required.

Conclusion: This study showed that combination therapy with PEG-IFN plus ribavirin was associated with a promising SVR rate and acceptable tolerability in Iranian patients. This regimen may be effective for patients who failed prior IFN-based treatment.

Keywords

Full Text

Full text is available in PDF

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani,

Babak Haghpanah,

Ali Reza Sayyah,

Ali Asad Hashtroudi,

Mohammad Bashashati,

Parisa Poursamimi

,et al.

Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:

30

Sep

2004

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Mohammad Reza Zali,

Hamid Mohaghegh Shalmani,

Mohsen Norouzinia,

Amir Hooshang MohammadAlizadeh,

Azita Nowroozi,

Negar Behrouz

Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:

1

Jan

2006

Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study

SM Alavian,

A Kabir,

B Hajarizadeh,

M Nayebpour,

T Dorodi,

FE Baralle

Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T, et al. Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study. Shiraz E-Med J. 2006;7(1):20390. doi:

1

Jan

2015

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi,

Seyed Moayed Alavian,

Maryam Keshvari

Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955

14

Dec

2013

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Zaigham Abbas,

Ghiasun Nabi Tayyab,

Mustafa Qureshi,

Mohammad Sadik Memon,

Amna Subhan,

Tanzila Shakir

,et al.

Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin. Hepat Mon. 2013;13(12):e14146. doi: https://doi.org/10.5812/hepatmon.14146

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 2 weeks ago
Scopus by Title: 0
Last Update: 2 weeks ago
Scopus by Title (Ref): 7
Last Update: 2 weeks ago
CrossRef: 0
Last Update: 4 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Seyed Alavian:[PubMed][Scholar]
Behzad Hajarizadeh:[PubMed][Scholar]
Bashir Hajibeigi:[PubMed][Scholar]
Taher Doroudi:[PubMed][Scholar]
Amir Hamadanizadeh:[PubMed][Scholar]
Koroush Abar:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Abstract

Full Text

Similar Articles

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 4 days ago